

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Recombinant Anti-Folate Binding Protein/FBP antibody [EPR20277]

RRID:AB_2920895

Type: Antibody

Proper Citation

Abcam Cat# ab221543, RRID:AB_2920895

Antibody Information

URL: http://antibodyregistry.org/AB_2920895

Proper Citation: Abcam Cat# ab221543, RRID:AB_2920895

Target Antigen: Folate Binding Protein

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: WB, IHC-P

Antibody Name: Recombinant Anti-Folate Binding Protein/FBP antibody [EPR20277]

Description: This monoclonal targets Folate Binding Protein

Target Organism: rat, mouse, human

Clone ID: EPR20277

Antibody ID: AB_2920895

Vendor: Abcam

Catalog Number: ab221543

Record Creation Time: 20231110T031346+0000

Record Last Update: 20260831T232005+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Folate Binding Protein/FBP antibody [EPR20277].

No alerts have been found for Recombinant Anti-Folate Binding Protein/FBP antibody [EPR20277].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. iScience, 29(7), 116390.

Hosni R, et al. (2025) The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma. Molecular cancer therapeutics, 24(11), 1775.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR α -Targeted TOP1i-Loaded ADC, for the Treatment of FR α -Expressing Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5261.